01 / Company statusDisclosed
Planckchron is founder-led, early-stage, and pre-revenue.
Canonical company facts and public company-state language.
Evidence registry / Public diligence
Evidence before promotion.
Planckchron distinguishes disclosed company facts, strategy, research targets, prototype observations, and independently reviewable results. No technical metric is represented as validated without a dated method, test conditions, limitations, and supporting evidence.
FactsCorporate and operating statements supported by records
StrategyManagement choices and sequencing—not achieved results
TargetsFuture objectives clearly separated from present capability
Validated resultsPublished only with method, limits, date, and evidence
Public claims register
What is known—and what is not yet proven.
This register is deliberately conservative. A missing benchmark is preferable to an unsupported benchmark because credibility compounds only when public claims survive diligence.
02 / Portfolio maturityDisclosed
Each program is labeled as research, design/prototype, or prototype stage.
Canonical investment-readiness registry used across public investor and proof pages.
03 / HERA NexusStrategy
HERA is the near-term commercial wedge for the portfolio.
18-month de-risking plan and design-partner validation sequence.
04 / Technical benchmarksNot yet validated
No public qubit, gate-fidelity, AI-accuracy, screening-throughput, or drug-candidate result is represented as validated.
Metrics remain unpublished until a dated method, conditions, limitations, and reproducible result are available.
05 / Commercial tractionNot yet validated
No established revenue, paid pilot, or signed customer contract is publicly represented at this time.
Commercial claims will be updated only after documentary evidence exists.
Canonical maturity register
One portfolio. One source of truth.
Every public investor and evidence page uses the same maturity labels, sequencing, objectives, and next evidence gates.
01 / Commercial wedgeResearch
HERA Nexus
Artificial intelligence. Validate one human-supervised intelligence workflow with a design partner and measurable operating outcomes.
Next evidence gate: Working prototype, named workflow owner, baseline measurement, and external review.
Review program
02 / Adjacent validationPrototype
EchoNet
Resilient communications. Demonstrate bounded coordination and graceful degradation in a controlled network environment.
Next evidence gate: Documented test method, network conditions, repeatable results, and failure analysis.
Review program
03 / Adjacent validationDesign & Prototype
Helios Autonomy
Autonomous systems. Test accountable perception, planning, escalation, and human intervention boundaries in simulation.
Next evidence gate: Scenario suite, intervention criteria, recorded decisions, and independent technical review.
Review program
04 / Long-horizon R&DDesign & Prototype
Aetherion Core
Emerging compute. Define and test the most consequential assumptions in the post-silicon and hybrid compute architecture.
Next evidence gate: Published architecture note, simulation method, reproducible model, and clearly labeled limitations.
Review program
05 / Long-horizon R&DResearch
BioForge + GenovaX
Biotechnology. Develop evidence-aware research workflows and identify one bounded biotechnology use case for external review.
Next evidence gate: Defined research question, responsible-review process, reproducible workflow, and qualified domain partner.
Review program
06 / Long-horizon R&DDesign & Prototype
PX-Phantom
Aerospace systems. Convert the aerospace thesis into a simulation-led research program with explicit engineering constraints.
Next evidence gate: Requirements baseline, simulation assumptions, engineering review, and dated test plan.
Review program
Validation standard
A result earns publication.
Planckchron's public standard is designed to prevent marketing language from outrunning technical reality.
Define the claim
State exactly what is being tested, what is excluded, and why the result matters.
Publish the method
Record the configuration, dataset, operating conditions, responsible reviewer, and known limitations.
Separate target from result
A projection, simulation, prototype observation, and validated benchmark must never share the same label.
Invite challenge
Material claims should be reproducible, reviewable, and corrected when stronger evidence becomes available.
18-month de-risking plan
Progress is measured by decisions earned.
The near-term plan prioritizes HERA Nexus while preserving all six programs behind explicit evidence gates.
0–3 months
Freeze the HERA v1 problem definition, customer profile, technical architecture, security boundary, and measurement plan.
Proceed only with a named accountable workflow and an external design-partner signal.4–6 months
Deliver a bounded HERA prototype with evidence capture, human approval, intervention controls, and audit history.
Proceed only if the prototype reduces a measurable workflow failure or operating burden.7–12 months
Run controlled design-partner evaluations and publish dated evidence records for the primary workflow.
Proceed only with retained use, credible user pull, and a defined path to a paid pilot.13–18 months
Convert validated use into paid pilot activity while advancing one EchoNet or Helios adjacent validation program.
Scale headcount and capital only when technical evidence, governance, and economics support expansion.Qualified diligence
Review the evidence behind the company—not a promotional proxy.
Qualified investors and aligned design partners may request the operating plan, capitalization materials, technical assumptions, milestone budget, and non-public evidence subject to eligibility and confidentiality.